MiMedx (MDXG) - Company Revenue

MiMedx Group, Inc. (MDXG) focuses on the production of regenerative biologics utilizing a complex cold-chain transportation system, which maintains high profitability. The company's current implementation level demonstrates business scaling dynamics, where the current value stands at 0.30. Stable demand for wound care renders the asset defensive, although regulatory changes in Medicare and patent disputes create certain risks.

MDXG MiMedx Corp: Company Revenue in the range 07/04/2022 - 11/15/2026

Analytical breakdowns for MiMedx Group, Inc.

- price and consensus price forecast:

Stock Price MiMedx Group, Inc.|MDXG - Analyst Consensus Forecast

- market capitalization indicators:

Market Value MiMedx Group|MDXG - Total Company Value

- book capitalization information:

Net Asset Value per Share MiMedx|MDXG - Company Book Value|Market Value to Book Value Ratio mimedx.com|MDXG - Company Total Assets

- company liabilities and liquidity data:

- business earnings and investment ratios data:

MDXG - Company Net Income|Future Profit MiMedx Group, Inc.|MDXG - P/E Multiple|Projected Price to Earnings Ratio MiMedx|MDXG - PEG Multiple|Enterprise Value to Operating Income Before Depreciation MiMedx Corp|MDXG - Operating profit before deduction of amortization|Earnings per share for the last 12 months MiMedx|MDXG - Net earnings per share for the last 12 months|Year-over-year earnings per one share growth for the last 12 months mimedx.com|MDXG - Earnings growth in current year|Net earnings per one share growth forecast for next year MiMedx Group, Inc.

- sales volume and revenue indicators:

MDXG - Company Revenue|Company Future Revenue mimedx.com|MDXG - Price-to-Revenue Ratio|Market Cap to Future Revenue Ratio MiMedx Corp|MDXG - Revenue Growth YoY (Last 12 Months)

Comprehensive company analysis:MDXG mimedx.com

The financial sales dynamics of MiMedx Group, Inc. (MDXG) reflect the effectiveness of commercializing placental biomaterials through a network of hospital contracts. This indicator captures the actual volume of daily revenue from the sale of specialized medical products. The daily transformation of data into a continuous trend reveals a hidden decline in margins despite externally stable demand. Growth in this metric confirms the performance of surgical sales teams and the demand for patented developments. The stable trajectory of this chart indicates high liquidity and the fundamental stability of the asset.

Analysis of competing companies